Literature DB >> 26117661

The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties.

Anna Schwendeman1, Denis O Sviridov2, Wenmin Yuan1, Yanhong Guo3, Emily E Morin1, Yue Yuan4, John Stonik2, Lita Freeman2, Alice Ossoli2, Seth Thacker2, Salena Killion5, Milton Pryor2, Y Eugene Chen3, Scott Turner5, Alan T Remaley2.   

Abstract

The goal of this study was to understand how the reconstituted HDL (rHDL) phospholipid (PL) composition affects its cholesterol efflux and anti-inflammatory properties. An ApoA-I mimetic peptide, 5A, was combined with either SM or POPC. Both lipid formulations exhibited similar in vitro cholesterol efflux by ABCA1, but 5A-SM exhibited higher ABCG1- and SR-BI-mediated efflux relative to 5A-POPC (P < 0.05). Injection of both rHDLs in rats resulted in mobilization of plasma cholesterol, although the relative potency was 3-fold higher for the same doses of 5A-SM than for 5A-POPC. Formation of preβ HDL was observed following incubation of rHDLs with both human and rat plasma in vitro, with 5A-SM inducing a higher extent of preβ formation relative to 5A-POPC. Both rHDLs exhibited anti-inflammatory properties, but 5A-SM showed higher inhibition of TNF-α, IL-6, and IL-1β release than did 5A-POPC (P < 0.05). Both 5A-SM and 5A-POPC showed reduction in total plaque area in ApoE(-/-) mice, but only 5A-SM showed a statistically significant reduction over placebo control and baseline (P < 0.01). The type of PL used to reconstitute peptide has significant influence on rHDL's anti-inflammatory and anti-atherosclerosis properties.

Entities:  

Keywords:  apolipoprotein A-I; atherosclerosis; high density lipoprotein; inflammation; peptides; sphingomyelin

Mesh:

Substances:

Year:  2015        PMID: 26117661      PMCID: PMC4548777          DOI: 10.1194/jlr.M060285

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  35 in total

1.  Reverse cholesterol transport is regulated by varying fatty acyl chain saturation and sphingomyelin content in reconstituted high-density lipoproteins.

Authors:  Philippe Marmillot; Sanket Patel; M Raj Lakshman
Journal:  Metabolism       Date:  2007-02       Impact factor: 8.694

2.  Native-native 2D gel electrophoresis for HDL subpopulation analysis.

Authors:  Lita A Freeman
Journal:  Methods Mol Biol       Date:  2013

3.  Western blots.

Authors:  Lita A Freeman
Journal:  Methods Mol Biol       Date:  2013

4.  Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities.

Authors:  Laurent Camont; Marie Lhomme; Fabiana Rached; Wilfried Le Goff; Anne Nègre-Salvayre; Robert Salvayre; Catherine Calzada; Michel Lagarde; M John Chapman; Anatol Kontush
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-03       Impact factor: 8.311

5.  Tweaking the cholesterol efflux capacity of reconstituted HDL.

Authors:  Cheng-I J Ma; Jennifer A Beckstead; Airlia Thompson; Anouar Hafiane; Rui Hao Leo Wang; Robert O Ryan; Robert S Kiss
Journal:  Biochem Cell Biol       Date:  2012-05-18       Impact factor: 3.626

6.  Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans.

Authors:  M Eriksson; L A Carlson; T A Miettinen; B Angelin
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

Review 7.  Unraveling the complexities of the HDL lipidome.

Authors:  Anatol Kontush; Marie Lhomme; M John Chapman
Journal:  J Lipid Res       Date:  2013-03-30       Impact factor: 5.922

Review 8.  Endothelial and antithrombotic actions of HDL.

Authors:  Chieko Mineo; Hiroshi Deguchi; John H Griffin; Philip W Shaul
Journal:  Circ Res       Date:  2006-06-09       Impact factor: 17.367

9.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

Authors:  Jean-Claude Tardif; Jean Grégoire; Philippe L L'Allier; Reda Ibrahim; Jacques Lespérance; Therese M Heinonen; Simon Kouz; Colin Berry; Russell Basser; Marc-André Lavoie; Marie-Claude Guertin; Josep Rodés-Cabau
Journal:  JAMA       Date:  2007-03-26       Impact factor: 56.272

10.  Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities.

Authors:  Anatol Kontush; Patrice Therond; Amal Zerrad; Martine Couturier; Anne Négre-Salvayre; Juliana A de Souza; Sandrine Chantepie; M John Chapman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-06-14       Impact factor: 8.311

View more
  39 in total

Review 1.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

2.  Egg yolk, source of bad cholesterol and good lipids?

Authors:  Robert S Rosenson; Wen-Liang Song
Journal:  Am J Clin Nutr       Date:  2019-09-01       Impact factor: 7.045

Review 3.  Reconstituted Discoidal High-Density Lipoproteins: Bioinspired Nanodiscs with Many Unexpected Applications.

Authors:  Maki Tsujita; Anna Wolska; Daniel A P Gutmann; Alan T Remaley
Journal:  Curr Atheroscler Rep       Date:  2018-11-05       Impact factor: 5.113

4.  Inkjet-printed micro-calibration standards for ultraquantitative Raman spectral cytometry.

Authors:  Vernon LaLone; Maria V Fawaz; Jomar Morales-Mercado; Márcio A Mourão; Catherine S Snyder; Sang Yeop Kim; Andrew P Lieberman; Anish Tuteja; Geeta Mehta; Theodore J Standiford; Krishnan Raghavendran; Kerby Shedden; Anna Schwendeman; Kathleen A Stringer; Gus R Rosania
Journal:  Analyst       Date:  2019-05-22       Impact factor: 4.616

5.  Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.

Authors:  Maria V Fawaz; Sang Yeop Kim; Dan Li; Ran Ming; Ziyun Xia; Karl Olsen; Irina D Pogozheva; John J G Tesmer; Anna Schwendeman
Journal:  J Pharmacol Exp Ther       Date:  2019-11-27       Impact factor: 4.030

6.  Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors.

Authors:  Sophia Morel; Jade Leahy; Maryse Fournier; Benoit Lamarche; Carole Garofalo; Guy Grimard; Floriane Poulain; Edgard Delvin; Caroline Laverdière; Maja Krajinovic; Simon Drouin; Daniel Sinnett; Valérie Marcil; Emile Levy
Journal:  J Lipid Res       Date:  2017-03-08       Impact factor: 5.922

7.  Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction.

Authors:  Francesca Zimetti; Stefano De Vuono; Monica Gomaraschi; Maria Pia Adorni; Elda Favari; Nicoletta Ronda; Maria Anastasia Ricci; Fabrizio Veglia; Laura Calabresi; Graziana Lupattelli
Journal:  J Lipid Res       Date:  2017-08-22       Impact factor: 5.922

8.  Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization.

Authors:  Jie Tang; Dan Li; Lindsey Drake; Wenmin Yuan; Sara Deschaine; Emily E Morin; Rose Ackermann; Karl Olsen; David E Smith; Anna Schwendeman
Journal:  J Lipid Res       Date:  2016-11-23       Impact factor: 5.922

9.  Amphipathic polyproline peptides stimulate cholesterol efflux by the ABCA1 transporter.

Authors:  D O Sviridov; S K Drake; L A Freeman; A T Remaley
Journal:  Biochem Biophys Res Commun       Date:  2016-02-12       Impact factor: 3.575

Review 10.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.